Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

HCRN LUN14-179

A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab (MK-3475) for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179

Status: Closed to Accrual

This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab (MK-3475), following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA or IIIB NSCLC. No randomization or blinding is involved.

  • Condition: Carcinoma, Non-Small Cell Lung
  • Intervention:
    • Drug: Pembrolizumab
  • Phase: Phase 2

For full description, see www.clinicaltrials.gov.

Read news release about this trial.

Watch a video about this trial:

Manuscripts/Articles:

  • Durm, GA, Jabbour, SK, Althouse, SK, Liu, Z, Sadiq, AA, Zon, RT, Jalal, SI, Kloecker, GH, Williamson, MJ, Reckamp, KL, Langdon, RM, Kio, EA, Gentzler, RD, Adesunloye, BA, Harb, WA, Walling, RV, Titzer, ML, Hanna, NH. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN14-179. Cancer. 2020: 126: 4353– 4361. https://doi.org/10.1002/cncr.33083. See abstract.
  • Bilal Anouti, Sandra Althouse, Greg Durm, Nasser Hanna. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179. Clinical Lung Cancer, Volume 21, Issue 3, 2020, Pages 288-293, ISSN 1525-7304, https://doi.org/10.1016/j.cllc.2019.06.009. See abstract.
  • S.S. Ahmed, G.A. Durm, J. Donatelli, Y. Liu, H. Yao, C. Desrosiers, Z. Liu, F.M. Kong, N. Hanna. Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN 14-179 Trial. Journal of Thoracic Oncology, Volume 12, Issue 11, S1552. See abstract.

Abstracts/Posters/Presentations:

  • N Shukla, SK Althouse, AA Sadiq, SI Jalal, SK Jabbour, R Zon, GH Kloecker, WB Fisher, KL Reckamp, EA Kio, RM Langdon, B Adesunloye, RD Gentzler, NH Hanna, GA Durm. The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN 14-179. Presented as a poster at the 2020 American Society of Clinical Oncology Annual Meeting. See abstract.
  • G. Durm, S. Althouse, A. Sadiq, S. Jalal, S. Jabbour, R. Zon, G. Kloecker, M. Williamson, K. Reckamp, E. Kio, R. Langdon, B. Adesunloye, R. Gentzler, W. Harb, R. Walling, C. Yeon, M. Koczywas, N. Hanna. P1.18-05 ChemoXRT w/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy. Presented at the IASLC 2019 World Conference on Lung Cancer. See abstract.
  • GA Durm, SK Althouse, AA Sadiq, SI Jalal, S Jabbour, R Zon, GH Kloecker, WB Fisher, KL Reckamp, EA Kio, RM Langdon, B Adesunloye, RD Gentzler, NH Hanna. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Presented at the Oral Abstract Session at the 2018 ASCO Annual Meeting on Monday, June 4, 2018. J Clin Oncol 36, 2018 (suppl; abstr 8500). See abstract.
  • G.A. Durm, E.A. Kio, W.B. Fisher, M.L. Titzer, S.Jabbour, T.Breen, Z.Liu, N.H. Hanna. Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN 14-179. Accepted as a publication-only abstract at the ASCO Annual Meeting, June 3-7, 2016, Chicago IL. J Clin Oncol 34, 2016 (suppl; abstr e20025). See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.